CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that a specialty-focused, research-based biopharmaceutical company headquartered in the United States has purchased Instem’s submit™ software solution suite. The company has selected submit to generate and manage SEND (The Standard for Exchange of Nonclinical Data) compliant data and documents.
The new client evaluated a range of SEND management tools on the market, including those provided by their existing preclinical IT vendor. Instem was selected because of their SEND leadership position and submit product functionality, especially the ability to extract data from the organization’s 3rd party preclinical data management system and create SEND datasets.
Instem is a leading supplier of IT applications and services to the early development healthcare market delivering compelling solutions for data collection, analysis and regulatory submissions management. Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions and consulting services increases client productivity by enhancing product development processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.
To learn more about Instem solutions and its mission, please visit www.instem.com.